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Abstract
Background: The detection of CA125 has been used in the follow up of ovarian cancer. At present, some scholars
believe that serum CA125 has no clinical value for the follow-up monitoring the recurrence for postoperative
patients with epithelial ovarian cancer, but in our clinical follow-up found that when the serum CA125 value is <35
U/ml, postoperative patients of epithelial ovarian carcinoma had already showed recurrent lesions in some
ecological and imaging examinations or in laparotomy exploration and biopsy, and we given the patients timely
treatment, the prognosis were improved.
Methods: Retrospective analysis the values of serum CA125 of 342 postoperative patients of epithelial ovarian
carcinoma, consisting of 296 non-recurrent and 46 recurrent cases, as well as 3175 cases of menopausal women
and 603 cases of postoperative patients of gynecological malignant tumor for the follow-up from January 2005 to
December 2016.
Results: The median value of CA125 for non-recurrent patients of epithelial ovarian carcinoma is 8.9 U/ml, the
median value of CA125 for non-recurrent patients of epithelial ovarian carcinoma is 29.7 U/ml; for menopausal
women, 8.1 U/ml; and for postoperative patients of gynecological malignant tumor, 7.2 U/ml, whereas the mean ±
standard deviation is 9.0 ± 1.9 U/ml, 31.3 ± 16.2U/ml, 8.0 ± 1.1 U/ml, and 6.8 ± 2.1 U/ml, respectively.
Conclusions: If the value of the CA125 for postoperative patients of epithelial ovarian carcinoma between 10 and
35 U/ml indicates a relative risk of recurrence. When the value of CA125 is higher than 10 U/ml and continuously
increased, need to be vigilant and should be combined with imaging examination (PET-CT). This result may
improve the prognosis for recurrent patients because of the early detection of recurrent lesions and early
retreatment.
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Background
CA125 is a glycoprotein antigen recognized using
OVCA433 as the antigen for preparing the murine
monoclonal antibody OC125 in epithelial ovarian carcin-
oma. It was first reported by the American scientist Bast
in 1981 [1]. The detection of CA125 has become an
effective way to diagnose ovarian epithelial carcinoma
and to monitor its condition changes over the years. In
2003, the Gynecologic Oncology Branch of the Chinese
Medical Association developed the following standard
indicators for the diagnosis and treatment of recurrent
ovarian malignant tumor: (1) increased tumor markers,
(2) appearance of ascites and pleural effusion, (3) mass
revealed by physical examination, (4) tumor revealed by
imaging examination, and (5) unknown cause of intes-
tinal obstruction. The presence of one indicator suggests
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recurrence, whereas the presence of two or more indi-
cates tumor recurrence [2].
Observation of the dynamic change in CA125 to
monitor the recurrence of epithelial ovarian carcinoma
is widely used in clinics, At present, some scholars
believe that serum CA125 has no clinical value for the
follow-up monitoring the recurrence for postoperative
patients with epithelial ovarian cancer [3], they estab-
lished the benefits of early treatment on the basis of
increased CA125 concentrations compared with delayed
treatment on the basis of clinical recurrence, the result
showed no evidence of a survival benefit with early treat-
ment of relapse on the basis of a raised CA125 concen-
tration alone. In their treatment, the patients were only
treated by chemotherapy, but not surgery. It is known
that ovarian cancer is mainly treated by surgery, our
clinical follow-up found that when the serum CA125
value is <35 U/ml, some postoperative patients of epi-
thelial ovarian carcinoma who underwent cytoreductive
or radical surgery and chemotherapy show recurrent
lesions in gynecological and imaging examinations or in
laparotomy exploration and biopsy, early detected the
lesions, the patients had the opportunity for surgery, the
prognosis were improvement and the survival time were
prolonged.
The present study aims to observe the dynamic moni-
toring of serum CA125 values in postoperative patients
of epithelial ovarian carcinoma with timely imaging
examination, early detection of small recurrent lesions,
early treatment, improvement of treatment effect, and
prolonged survival time.
Methods
The subjects of this investigation are 342 patients treated
from January 2005 to December 2016 who have been diag-
nosed with epithelial ovarian carcinoma by pathology
examination and have been detected with serum CA125
during and after chemotherapy. The patients’age ranges
from 19 to 83 years old, and the median age is 50 years old.
The follow-up time is 12–144 months, and the median
time is 76 months. Of the 342 subjects, 192 had serious
cystadenocarcinoma;26,mucinous cystadenocarcinoma; 32,
endometrial adenocarcinoma; 23, clear cell carcinoma; 66,
mixed type cases; and 3, undifferentiated carcinoma. The
criteria and guideline for surgical pathology staging were
provided by the International Federation of Gynecology
and Obstetrics (FIGO) (Table 1). Seven cases involving
young patients opted to retain their reproductive functions,
whereas the rest underwent satisfactory cytoreductive
surgery (residual tumor lesions ≤1 cm) and received
platinum-based chemotherapy after. Each patient regularly
underwent CA125 test, gynecological examination, abdom-
inal ultrasound, chest radiograph, or CT/MRI/PET exami-
nations before and after chemotherapy.
Three thousand one hundred seventy-five cases of
menopausal women without complications were selected,
whereas 603 postoperative patients of gynecological ma-
lignant tumor, except epithelial ovarian tumor, were
chosen as the control group. The menopausal women’s
age ranges from 50 to 88 years old, and the median age is
59 year old. The postoperative patients’ age ranges from
26 to 73 years old, and the median age is 50. The follow-
up time is 12–144 months, and the median time is
76 months.
The levels of CA125 for all patients before operation were
all >35 U/ml and received regulated the platinum-based
combination chemotherapy after operation, regular follow-
up, and monthly monitoring of CA125, every 3 months ac-
cepted clinical and imaging examinations. Blood samples
measuring 2 ml were used as separation serum. Automatic
chemiluminescent immunoassay analyzer Siemens Centaur
XP auxiliary reagent was used to detect the concentration
of CA125, observing the dynamic changes in CA125 in
gynecological and imaging examination. SPSS 13.0 software
was used for statistical analysis. Count data were analyzed
by χ2 test, with P <0.05 considered statistically significant.
Results
1. Value distribution of serum CA125 in
postmenopausal women
The range of serum CA125 in 3175 cases of meno-
pausal women is 2–29.1 U/ml, the median is 8.1 U/ml,
Table 1 Pathological type distribution of epithelial ovarian carcinoma patients
Category Pathology staging
I II III IV Total
Serous cystadenocarcinoma 15(7.8) 23(12.0) 145(75.5) 9(4.7) 192(56.1)
Mucinous cystadenocarcinoma 9(34.6) 3(11.5) 14(53.9) 0(0) 26(7.6)
Endometrial adenocarcinoma 11(34.4) 5(15.6) 16(50.0) 0(0) 32(9.4)
Clear cell carcinoma 19(82.6) 0(0) 4(17.4) 0(0) 23(6.7)
Mixed type and undifferentiated carcinoma 26(37.7) 24(34.8) 19(27.5) 0(0) 69(20.2)
Total 80(23.4) 55(16.1) 198(57.9) 9(2.6) 342(100.0)
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and the mean ± standard deviation is 8.0 ± 1.1 U/ml
(Table 2). The CA125 ≤ 10 U/ml in the total proportion
of postmenopausal women is 3134/3175 (98.7%).
2. Value distribution of serum CA125 in non-recurrent
postoperative patients of gynecological malignant
tumor
There were 603 cases of non-recurrent postoperative
patients of gynecological malignant tumor, except epi-
thelial ovarian tumor patients who were ovariectomized.
The follow-up time is 12–144 months, and the median
time is 76 months. From this group, 33 had fallopian
tube cancer; 167, endometrial cancer; and 403, cervical
cancer (Table 3). The range of CA125 is 4.1–20.8 U/ml,
the median is 7.2 U/ml, and the mean ± standard devi-
ation is 6.8 ± 2.1 U/ml(Table 2).
3. Value distribution of serum CA125 in non-recurrent
postoperative patients of epithelial ovarian
carcinoma
There were 296 cases of non-recurrent patients in
the total proportion of epithelial ovarian carcinoma
(86.5%). The follow-up time is 12–144 months, and
the median time is 76 months. The dynamics of
changes in CA125 levels is 2–34.9 U/ml, the median
is 8.9 U/ml, and the mean ± standard deviation is 9.0
± 1.9 U/ml(Table 2). Statistical analysis of the CA125
values of non-recurrent postoperative epithelial ovar-
ian carcinoma patients and postmenopausal women
and the non-recurrence of gynecological malignant
tumor patients showed no significant difference (P >0.05).
The postoperative CA125 values were divided into four
groups:≤10 U/ml, 10–20 U/ml, 20–35 U/ml, and ≥35 U/
ml. There were 275 cases of epithelial ovarian carcinoma
non-recurrent patients whose CA125 ≤ 10 U/ml (275/296,
92.9%) (Table 4).
4. Value distribution of serum CA125 in recurrent
postoperative patients of epithelial ovarian
carcinoma
There were 46 cases of recurrent patients in the
total proportion of epithelial ovarian carcinoma pa-
tients (13.5%). The follow-up time is 12–144 months,
and the median time is 76 months. The dynamics of
changes in CA125 levels is 10.2–82.8 U/ml, the me-
dian is 29.7 U/ml, and the mean ± standard deviation
is 31.3 ± 16.2 U/ml (Table 2). The postoperative
CA125 values were divided into four groups:≤10 U/
ml, 10–20 U/ml, 20–35 U/ml, and ≥35 U/ml (Table 4),
the CA125 ≤ 35 U/ml in the total proportion of recur-
rent postoperative patients of epithelial ovarian car-
cinoma when found the recurrent lesions is 31/46
(67.4%).. When the value of CA125 is higher than 10
U/ml and continuously increased, general the time
from starting elevation of CA125 to recurrences were
2 to 3 months,need to be vigilant and should be com-
bined with imaging examination (PET-CT). Three
cases of recurrent patients was found the recurrent lesions
by PET examination when the value of CA125 is 14.5 U/
ml, 13.5 U/ml, and 20.9 U/ml, and the recurrent lesions
was found in the spleen (Fig. 1), in the liver (Fig. 2), and in
the pelvic (Fig. 3), respectively, after the second surgery,
up to now, the values of CA125 are all less than 10 U/ml
and the patients were all alive so far.
Discussion
Serum CA125 is mainly found in mesothelial cells
and Miller tubular epithelial tissues, including peri-
toneal, pleural, pericardial, fallopian tube, endometrial,
Table 3 Value distribution of serum CA125 in ovariectomized, non-recurrent, postoperative patients of gynecological malignant tumor
Type Pathology staging Total CA125 level(U/ml)
I II III IV Range Median X ± S
Fallopian tube cancer 3 7 17 6 33(5.5) 4.1 ~ 12.0 7.4 8.1 ± 2.4
Endometrial cancer 55 88 21 3 167(27.7) 3.1 ~ 15.1 7.0 7.3 ± 2.8
Cervical cancer 152 200 34 17 403(66.8) 3.5 ~ 20.8 6.6 6.7 ± 2.2
Total 210 295 72 26 603(100) 4.1 ~ 20.8 7.2 6.8 ± 2.1





Epithelial ovarian carcinoma patients Non-recurrent patients of
gynecological malignant tumor
Non-recurrent (N = 296) Recurrent (N = 46) (N = 603)
Rang 2 ~ 29.1 2.0 ~ 34.9 10.2 ~ 82.8 4.1 ~ 20.8
Median 8.1 8.9 29.7 7.2
X ± S 8.0 ± 1.1 9.0 ± 1.9 31.3 ± 16.2 6.8 ± 2.1
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and cervical tissues. It acts as an antigen not only for
ovarian carcinoma but also for inflammatory response
disease that comes from mesothelial cells and Miller
tubular epithelial tissues [4]. Postmenopausal women
and non-recurrent postoperative patients of gynecological
malignant tumor almost do not contract CA125-related
diseases, such as pelvic inflammatory disease, endometri-
osis, peritonitis, etc. Therefore, without any complication
cases, the range of CA125 is consistent with that of non-
recurrent postoperative patients of epithelial ovarian
carcinoma.
James reported 11 epithelial ovarian cancer patients
whose histological or radiological examination re-
vealed recurrence, their serum CA125 continuously
increased three times within the normal range from
one to 3 months [5]. In the present study, the median
values of CA125 for non-recurrent patients of epithe-
lial ovarian carcinoma, menopausal women and post-
operative patients of gynecological malignant tumor
are all less than 10 U/ml. The CA125 ≤ 10 U/ml in
the total proportion of postmenopausal women is
3134/3175 (98.7%), The CA125 ≤ 10 U/ml in epithelial
ovarian carcinoma non-recurrent patients is 275/296
(92.9%), statistical analysis of the CA125 values of
non-recurrent postoperative patients of epithelial
ovarian carcinoma and postmenopausal women and
non-recurrent patients of gynecological malignant
tumor showed no significant difference (P >0.05). The
CA125 in 31 cases of recurrent patients of epithelial
ovarian carcinoma whose CA125 ≤ 35 U/ml continu-
ously increased within the normal range before recur-
rence, consistent with the report. Among recurrent
patients, before recurrent the value of CA125 were all
less than 10 U/ml and when the CA125 were con-
tinuously increased and combined with imaging
examination (PET-CT), three cases of recurrent pa-
tients was found the recurrent lesions by PET exam-
ination when the value of CA125 is 14.5 U/ml, 13.5




N (%) Range Median X ± S N (%) Range Median X ± S
10≥ 275(92.9) 2 ~ 10 6.9 6.2 ± 1.8 (0)0 _ _ _
20 ~ 10 15(5.1) 10.3 ~ 16.4 14.1 12.9 ± 2.1 16(34.8) 10.2 ~ 18.9 15.3 14.2 ± 2.5
35 ~ 20 6(2.0) 25 ~ 34.9 27.1 26.7 ± 3.1 15(32.6) 21.1 ~ 34.8 24.4 24.2 ± 3.4
35< (0)0 _ _ _ 15(32.6) 35.1 ~ 82.8 46.8 49.6 ± 11.9
Fig. 1 The recurrent lesions was found in the spleen by PET examination when the value of CA125 is 14.5 U/ml
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Fig. 2 The recurrent lesions was found in the liver by PET examination when the value of CA125 is 13.5 U/ml
Fig. 3 The recurrent lesions was found in the pelvic by PET examination when the value of CA125 is 20.9 U/ml
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U/ml, and 20.9 U/ml, respectively, we found the re-
current lesions early and the patients had the oppor-
tunity for surgery, after the second surgery, up to
now, the values of CA125 are all less than 10 U/ml
and the patients were all alive so far.
Low reported that in 76 cases of postoperative patients
with epithelial ovarian carcinoma followed up in 1 year, 68
revealed recurrence by MRI, 24 (35.3%) of which have a
CA125 ≤ 35 U/ml [6]. Garcia-Velloso reported that 55
cases of postoperative patients of epithelial ovarian carcin-
oma revealed recurrence by PET, 11 of which have
CA125 ≤ 35 U/ml (11/55, 20.0%) [7]. Crawford reported
106 cases of postoperative patients of epithelial ovarian
carcinoma. The median survival time of patients whose
CA125 ≤ 10 U/ml is 2968 days, those whose CA125 is be-
tween 11 and 20 U/ml is 537 days, and those whose
CA125 is between 21 and 30 U/ml is 537 days. They
correspondingly proposed that when patients have
CA125 ≤ 10U/ml, the recurrence rate is low and prognosis
is good [8]. Bese reported 45 cases of postoperative pa-
tients of epithelial ovarian carcinoma, of which 28 who
had CA125 ≥ 20 U/ml based on gynecological examin-
ation and imaging examination did not show recurrence,
but the second exploratory surgery found recurrence [9].
Sugiyama reported 62 cases of postoperative patients of
epithelial ovarian carcinoma using 20 U/ml as the cut-off
value to monitor recurrence and for early detection of re-
current lesions [10]. In comparison, this study examined
46 cases of recurrent postoperative patients of epithelial
ovarian carcinoma, 31 of which have CA125 ≤ 35 U/ml
(31/46, 67.4%). According to our study, the detection
value of CA125 in patients with ovarian epithelial cancer
after surgery is necessary, it can be found the recurrent le-
sions timely, timely treatment, so as not to delay the treat-
ment time. This is different from some scholars’ point of
view, some scholars believe that serum CA125 has no
clinical value for the follow-up monitoring the recurrence
for postoperative patients with epithelial ovarian cancer
[3], they established the benefits of early treatment on the
basis of increased CA125 concentrations compared with
delayed treatment on the basis of clinical recurrence, the
result showed no evidence of a survival benefit with early
treatment of relapse on the basis of a raised CA125 con-
centration alone. In their treatment, the patients were only
treated by chemotherapy, but not surgery. It is known that
ovarian cancer is mainly treated by surgery, our clinical
follow-up found that when the serum CA125 value is <35
U/ml, some postoperative patients of epithelial ovarian
carcinoma who underwent cytoreductive or radical
surgery and chemotherapy show recurrent lesions in
gynecological and imaging examinations or in laparotomy
exploration and biopsy, early detected the lesions, the pa-
tients had the opportunity for surgery, the prognosis were
improvement and the survival time were prolonged.
Some scholars believe that women at familial/genetic
ovarian cancer risk often undergo screening despite un-
proven efficacy. each woman has her own CA125 base-
line, serum CA125 q3 months, evaluated using a risk of
ovarian cancer algorithm (ROCA), detected significant
increases above each subject’s baseline, which triggered
transvaginal ultrasound, ROCA q3 months had better
early-stage sensitivity at high specificity compared with
CA125 > 35 U/mL q6/q12 months [11], in our study, the
recurrence rate of epithelial ovarian carcinoma in post-
operative patients is high, and most cases of recurrence
involve large lesions, the time of treatment is also de-
layed. Patients are not sensitive to chemotherapy drugs,
the treatment is ineffective, and the prognosis is poor. If
the value of the CA125 for postoperative patients of
epithelial ovarian carcinoma between 10 and 35 U/ml
indicates a relative risk of recurrence. When the value of
CA125 is higher than 10 U/ml and continuously in-
creased, need to be vigilant and should be combined
with imaging examination (PET-CT).early detected the
lesions, the patients had the opportunity for surgery.
Conclusions
When the value of CA125 is higher than 10 U/ml and
continuously increased, need to be vigilant and should
be combined with imaging examination (PET-CT), early
detection of recurrent lesions and early retreatment,
especially maybe have the opportunity for surgery, this
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